Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) is now available.
Lumos Diagnostics has entered into an agreement with WellStreet Urgent Care to advance the use of its FebriDx® testing through a joint venture with Piedmont Healthcare in Atlanta, Georgia. The program, set to begin in October 2025, will involve WellStreet procuring and submitting reimbursement claims for each test, with PHASE Scientific leading distribution and Pro-spectus managing billing data. The collaboration aims to provide operational insights and establish future coverage policies with national insurance organizations. If a CLIA waiver is granted, the initiative could expand to approximately 140 WellStreet locations across the US, enhancing Lumos’ market presence and operational scalability.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology, aiding healthcare professionals in diagnosing and managing medical conditions. The company offers customized assay development, manufacturing services for point-of-care tests, and proprietary digital reader platforms. Lumos also develops, manufactures, and commercializes its own branded point-of-care tests targeting infectious and inflammatory diseases.
Average Trading Volume: 8,091,500
Technical Sentiment Signal: Buy
Current Market Cap: A$137.5M
For an in-depth examination of LDX stock, go to TipRanks’ Overview page.